We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+2.8%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$798M
AUM Growth
-$4.25M
Cap. Flow
+$13.3M
Cap. Flow %
1.67%
Top 10 Hldgs %
99.98%
Holding
13
New
–
Increased
3
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$6.31M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.1M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$3.74M

Top Sells

Rank Stock Value
1
CYCN icon
Cyclerion Therapeutics
CYCN
+$2.86M

Sector Composition

Rank Sector Weight
1 Healthcare 73.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
1
DELISTED
Medicines Co
MDCO
$210M 26.33%
4,202,000
– –
AGN
2
DELISTED
Allergan plc
AGN
$175M 21.99%
1,042,500
– –
BIIB icon
3
Biogen
BIIB
$30B
$150M 18.76%
643,000
– –
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$696M
$86.7M 10.87%
10,103,000
+385,000
+4% +$3.74M
INVA icon
5
Innoviva
INVA
$1.55B
$65.8M 8.25%
6,242,000
– –
ICPT
6
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$56.5M 7.08%
851,000
+94,000
+12% +$6.31M
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$15.9B
$31M 3.89%
242,000
+45,500
+23% +$6.1M
PBYI icon
8
Puma Biotechnology
PBYI
$404M
$15.3M 1.91%
1,417,000
– –
MRSN
9
DELISTED
Mersana Therapeutics
MRSN
$5.92M 0.74%
150,000
– –
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$1.33M 0.17%
185,185
– –
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$77K 0.01%
1,000
– –
ABBV icon
12
AbbVie
ABBV
$443B
$75K 0.01%
1,000
– –
CYCN icon
13
Cyclerion Therapeutics
CYCN
$14.9M
– –
-12,500
Closed -$2.86M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sarissa Capital Management held 13 positions worth $798M, down 0.53% from $802M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management's Q3 2019 filing shows 3 increased and 1 closed positions. The largest sale was Cyclerion Therapeutics, an estimated $2.86M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 81% a quarter earlier.

  • Sarissa Capital Management added most to Intercept Pharmaceuticals, Inc. in Q3 2019, an estimated $6.31M increase.
  • Sarissa Capital Management fully exited Cyclerion Therapeutics in Q3 2019, selling an estimated $2.86M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $798M portfolio in Q3 2019.
  • Sarissa Capital Management opened 0 new positions and closed 1 in Q3 2019.
  • Sarissa Capital Management's portfolio value fell 0.53% quarter-over-quarter to $798M.

Based on Sarissa Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.